No.

Publication Date

Citing Article

1

2026

Jamie Feng, Sameena Khan, Thomas K. Waddell, Kazuhiro Yasufuku, Zachary Coyne, Deirdre Kelly, Nicholas Meti, Najib Safieddine, Michael Ko, Andrew Pierre, Shaf Keshavjee, Elliot Wakeam, Laura Donahoe, Marcelo Cypel, Jonathan Yeung, Marc de Perrot, Negar Ahmadi, Sayf Gazala, Carmine Simone, David Parente, Mary R. Rabey, Jennifer H. Law, Janice J.N. Li, Alexandra Salvarrey, Lisa W. Le, Andrew Seto, Michael Cabanero, Ming-Sound Tsao, Christodoulos Pipinikas, Amber Chevalier, Scott V. Bratman, Natasha B. Leighl. Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay, Journal of Thoracic Oncology. 2026; 103645103645.  https://doi.org/10.1016/j.jtho.2026.103645

2

2026

M. Zeeshan Ozair, Nitin Ohri. Adding Immunotherapy and Targeted Therapy to Chemoradiotherapy for Non-small Cell Lung Cancer, Thoracic Surgery Clinics. 2026; 36: 83.  https://doi.org/10.1016/j.thorsurg.2025.09.002

3

2024

Robert Roskoski Jr., Targeted and cytotoxic inhibitors used in the treatment of lung cancers, Pharmacological Research. 2024; 209: 107465107465.  https://doi.org/10.1016/j.phrs.2024.107465

4

2025

Yuzhu Chen, Fei Qi, Chenhao Sun, Peng Jiang, Xiangyu Xue, Xiaomei Yang, Xiaomi Li, Xin He, Yishuo Wang, Tongmei Zhang. Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies, Therapeutic Advances in Medical Oncology. 2025; 17: 17588359241312501.  https://doi.org/10.1177/17588359241312501

5

2025

Giorgio Facheris, Gianluca Cossali, Jessica Imbrescia, Salvatore La Mattina, Eneida Mataj, Nicole Meli, Giulia Volpi, Luca Triggiani, Andrea Emanuele Guerini, Guido Levi, Salvatore Grisanti, Michela Buglione di Monale e Bastia, Paolo Borghetti. Real-World Insights into the Impact of Durvalumab on Stage III Unresectable Non-Small Cell Lung Cancer—A Narrative Review, Cancers. 2025; 17: 874.  https://doi.org/10.3390/cancers17050874